Remodulin Logo
Remodulin Logo
Orenitram PIRemodulin PI

01

About Eleanor

Eleanor, who was diagnosed with IPAH 2 years ago with high risk status, presents now for regular PAH follow-up.

  • After diagnosis, patient was prescribed SC Remodulin, in addition to oral background therapy, and has been in low risk for the past year.
  • Patient reports no changes in her overall health since her previous visit—no chest pressure, no dizziness.
    • Patient can complete routine activities around the house and is able to perform her job; she experiences occasional breathlessness when taking stairs or walking more than a couple of blocks.
  • Patient complains of bothersome site pain when starting a new infusion site and finds her pump inconvenient. She changes infusion sites infrequently (once a month) and manages site pain with a combination of topical and systemic remedies.

Current Remodulin dose: 52 ng/kg/min; no titration within the last 6 months